of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma[...
NHL)最主要的组成部分,约为80.6%;其中以弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)、滤泡性淋巴瘤(follicular lymphoma,FL)、黏膜相关淋巴组织淋巴瘤(mucosa-associated lymphoid tissue lymphoma,MALT)、小淋巴细胞淋巴...
大量研究已证实CD20是人类B淋巴细胞表面特异性分子标记物，对B淋巴细胞的增殖和分化具有调节作用。绝大部分的B淋巴细胞瘤都有CD20的表达，CD20分子易与抗体结合，且结合后不易脱落、不内化，成为治疗B细胞淋巴瘤的理想靶抗原。目前，抗CD20单克隆抗体是治疗B细胞淋巴瘤（B-cell non-Hodgkin’s lymphoma）的重要靶向药...
最常见的NHL是弥漫性大B细胞淋巴瘤(Diffuse Large B Cell Lymphoma, DLBCL)和滤泡性淋巴瘤(Follicular Lymphoma, FL)。DLBCL是一种侵袭性B细胞淋巴瘤,大约30%左右NHL属于该类型;滤泡性淋巴瘤是一种惰性淋巴瘤,大约25%的NHL属于该类型。另外,常见的NHL类型还包括边缘区B细胞淋巴瘤(Marginal Zone B-cell Lymphoma)...
2.该研究报告了迄今为止使用双特异性抗体治疗 B-NHL 的最长随访结果(3.5 年); 3.递加剂量组(B 组)中,iNHL 患者的 ORR 达 65.7%,aNHL 患者的 ORR 达 36.4%。 4.再治疗数据证实了 mosunetuzumab 在多线治疗中的潜...
[1] Shi, Yuankai,et al."Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial." Hematological O...
CD20 negatively converted B-cell malignant lymphoma cell line is provided. In addition, an animal model that reflects the pathology of CD20 negatively converted B-cell malignant lymphoma is provided. In addition, the screening method of the effective substance is also provided against CD20 negatively...
大量研究已证实CD20是人类B淋巴细胞表面特异性分子标记物,对B淋巴细胞的增殖和分化具有调节作用。绝大部分的B淋巴细胞瘤都有CD20的表达,CD20分子易与抗体结合,且结合后不易脱落、不内化,成为治疗B细胞淋巴瘤的理想靶抗原。目前,抗CD20单克隆抗体是治疗B细胞淋巴瘤(B-cell non-Hodgkin’s lymphoma)的重要靶向药(图...
【1】Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T. 2010 Mar;35(3):148-57. PMID: 20442809; PMCID: PMC2844047. 【2】Ciara L. Freeman,Laurie H. Sehn,A tale of two antibodies: obinutuzumab versus rituximab.British...
1.Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.2.Glofitamab CD20-TCB bispecific antibody.3.pharmiweb.com/press-rel approves-genentech-s-columvi-the-first-and-only-bispecific-antibody-with-a-fixed-duration-treat.4.fda.gov/drugs/resources. 5.罗氏血液病新药征途:做无人区的...